158 related articles for article (PubMed ID: 11279126)
1. Follistatin: essential role for the N-terminal domain in activin binding and neutralization.
Sidis Y; Schneyer AL; Sluss PM; Johnson LN; Keutmann HT
J Biol Chem; 2001 May; 276(21):17718-26. PubMed ID: 11279126
[TBL] [Abstract][Full Text] [Related]
2. The role of follistatin domains in follistatin biological action.
Keutmann HT; Schneyer AL; Sidis Y
Mol Endocrinol; 2004 Jan; 18(1):228-40. PubMed ID: 14563935
[TBL] [Abstract][Full Text] [Related]
3. Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins.
Wang Q; Keutmann HT; Schneyer AL; Sluss PM
Endocrinology; 2000 Sep; 141(9):3183-93. PubMed ID: 10965889
[TBL] [Abstract][Full Text] [Related]
4. Heparin and activin-binding determinants in follistatin and FSTL3.
Sidis Y; Schneyer AL; Keutmann HT
Endocrinology; 2005 Jan; 146(1):130-6. PubMed ID: 15471966
[TBL] [Abstract][Full Text] [Related]
5. Site-specific mutagenesis of human follistatin.
Inouye S; Guo Y; Ling N; Shimasaki S
Biochem Biophys Res Commun; 1991 Aug; 179(1):352-8. PubMed ID: 1883364
[TBL] [Abstract][Full Text] [Related]
6. The heparin binding site of follistatin is involved in its interaction with activin.
Sumitomo S; Inouye S; Liu XJ; Ling N; Shimasaki S
Biochem Biophys Res Commun; 1995 Mar; 208(1):1-9. PubMed ID: 7887917
[TBL] [Abstract][Full Text] [Related]
7. Follistatin and its role as an activin-binding protein.
Sugino H; Sugino K; Hashimoto O; Shoji H; Nakamura T
J Med Invest; 1997 Aug; 44(1-2):1-14. PubMed ID: 9395712
[TBL] [Abstract][Full Text] [Related]
8. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
[TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of native activin B.
Nakamura T; Asashima M; Eto Y; Takio K; Uchiyama H; Moriya N; Ariizumi T; Yashiro T; Sugino K; Titani K
J Biol Chem; 1992 Aug; 267(23):16385-9. PubMed ID: 1644823
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell.
Sugino K; Kurosawa N; Nakamura T; Takio K; Shimasaki S; Ling N; Titani K; Sugino H
J Biol Chem; 1993 Jul; 268(21):15579-87. PubMed ID: 8340384
[TBL] [Abstract][Full Text] [Related]
11. Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).
Arai KY; Tsuchida K; Li C; Watanabe G; Sugino H; Taya K; Nishiyama T
Protein Expr Purif; 2006 Sep; 49(1):78-82. PubMed ID: 16737827
[TBL] [Abstract][Full Text] [Related]
12. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors.
de Winter JP; ten Dijke P; de Vries CJ; van Achterberg TA; Sugino H; de Waele P; Huylebroeck D; Verschueren K; van den Eijnden-van Raaij AJ
Mol Cell Endocrinol; 1996 Jan; 116(1):105-14. PubMed ID: 8822271
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the activin-inhibin-follistatin system by bone morphogenetic proteins in the zebrafish ovary.
Li CW; Ge W
Biol Reprod; 2013 Sep; 89(3):55. PubMed ID: 23843234
[TBL] [Abstract][Full Text] [Related]
14. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Di Simone N; Crowley WF; Wang QF; Sluss PM; Schneyer AL
Endocrinology; 1996 Feb; 137(2):486-94. PubMed ID: 8593793
[TBL] [Abstract][Full Text] [Related]
15. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state.
McConnell DS; Wang Q; Sluss PM; Bolf N; Khoury RH; Schneyer AL; Midgley AR; Reame NE; Crowley WF; Padmanabhan V
J Clin Endocrinol Metab; 1998 Mar; 83(3):851-8. PubMed ID: 9506739
[TBL] [Abstract][Full Text] [Related]
16. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin.
Inouye S; Guo Y; DePaolo L; Shimonaka M; Ling N; Shimasaki S
Endocrinology; 1991 Aug; 129(2):815-22. PubMed ID: 1906804
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the existence of a local activin follistatin negative feedback loop in the goldfish pituitary and its regulation by activin and gonadal steroids.
Cheng GF; Yuen CW; Ge W
J Endocrinol; 2007 Dec; 195(3):373-84. PubMed ID: 18000300
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1beta regulates pituitary follistatin and inhibin/activin betaB mRNA levels and attenuates FSH secretion in response to activin-A.
Bilezikjian LM; Turnbull AV; Corrigan AZ; Blount AL; Rivier CL; Vale WW
Endocrinology; 1998 Jul; 139(7):3361-4. PubMed ID: 9645713
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids.
Krummen LA; Woodruff TK; DeGuzman G; Cox ET; Baly DL; Mann E; Garg S; Wong WL; Cossum P; Mather JP
Endocrinology; 1993 Jan; 132(1):431-43. PubMed ID: 7678220
[TBL] [Abstract][Full Text] [Related]
20. Activin-binding protein is present in pituitary.
Kogawa K; Nakamura T; Sugino K; Takio K; Titani K; Sugino H
Endocrinology; 1991 Mar; 128(3):1434-40. PubMed ID: 1900230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
